Edwyn
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | $1,988 | $2,418 | $2,531 | $2,965 | $3,366 |
| Gross Profit | $940 | $1,210 | $1,306 | $1,513 | $1,650 |
| Operating Income | $248 | $413 | $433 | $437 | $253 |
| Net Income | $158 | $277 | $297 | $427 | $113 |
Over the past five years, Bruker Corporation has shown a steady increase in revenue and gross profit. Between 2020 and 2024, revenue grew from USD 1,987.5 million to USD 3,366.4 million, indicating strong top‐line growth. Gross profit similarly trended upward from USD 939.8 million in 2020 to USD 1,649.5 million in 2024, reflecting efficient cost of goods sold management in an environment of expanded sales. From 2020 to 2023, operating income and net income also increased, with operating income rising from USD 248.3 million to USD 436.9 million and net income from USD 157.8 million to USD 427.2 million, suggesting that the company was able to leverage higher revenues into stronger earnings, possibly benefiting from favorable market conditions and operational efficiencies. Year-over-year changes during this period demonstrated healthy growth percentages, though the increments tended to moderate slightly as the base increased. However, the 2024 performance diverged from the earlier trends; despite the continuance of increased revenue and gross profit, operating income fell sharply to USD 253.1 million—a drop of nearly 42% from 2023—and net income plummeted to USD 113.1 million. Such significant declines, each exceeding 20% year-over-year, imply that rising expenses, increased operational costs, or other unfavorable factors may have eroded profitability in 2024. Overall, while Bruker Corporation’s revenue and gross profit expansion suggest robust market demand and a solid business model, the marked deterioration in operating and net margins in 2024 calls for closer examination. Nonetheless, the company’s overall financial health remains generally strong, albeit facing short-term profitability headwinds that warrant further strategic review.
This analysis is for informational purposes only and does not constitute financial advice or recommendations for any investment decisions. Please consult with a qualified financial professional for personalized guidance.